Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-29
2008-01-29
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009100
Reexamination Certificate
active
10546758
ABSTRACT:
Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease with avoiding toxicity and leading to clinical improvement.
REFERENCES:
patent: 4959175 (1990-09-01), Yatzidis
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 5849704 (1998-12-01), Sorensen et al.
patent: 5932189 (1999-08-01), Dean et al.
patent: 6011010 (2000-01-01), Scheuer et al.
patent: 2003/0157685 (2003-08-01), Zervos
patent: 2004/0052764 (2004-03-01), Hildinger et al.
patent: 2004/0067895 (2004-04-01), Faircloth et al.
patent: 2004/0214755 (2004-10-01), Albericio et al.
patent: 2005/0054555 (2005-03-01), Jimeno et al.
patent: 2006/0234920 (2006-10-01), Faircloth et al.
patent: 0 610 078 (1994-08-01), None
patent: 0 838 221 (1998-04-01), None
patent: WO 99/42125 (1999-08-01), None
patent: WO 2001/58934 (2001-08-01), None
patent: WO 2002/36145 (2002-05-01), None
patent: WO0236145 (2002-05-01), None
patent: WO 2003/033012 (2003-04-01), None
patent: WO 2004/035613 (2004-04-01), None
patent: WO 2005/023846 (2005-03-01), None
patent: WO 2005/103072 (2005-11-01), None
U.S. Appl. No. 10/182,881, filed Jun. 3, 2003, Fernando Albericio et al.
U.S. Appl. No. 11/587,177, filed Jan. 2, 2007, Andres Francesch Solloso et al.
U.S. Appl. No. 10/492,670, filed Nov. 3, 2004, Jose Jimeno.
U.S. Appl. No. 10/399,571, filed Nov. 14, 2003, Glynn Faircloth.
U.S. Appl. No. 10/642,006, filed Aug. 14, 2003, Paul Scheuer.
U.S. Appl. No. 10/570,734, filed Mar. 6, 2006, Fernando Albericio Palomera et al.
U.S. Appl. No. 10/531,533, filed Apr. 25, 2006, Glynn Faircloth et al.
Vippagunta et al., “Crystalline Solids,”Adv Drug Deliv Rev, vol. 48, iss. 1, pp. 3-26, May 16, 2001.
Nuijen B et al., “Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F” Drug Development and Industrial Pharmacy, vol. 27, No. 8, pp. 767-780, 2001.
Faircloth G et al., “Preclinical development of kahalalide F, a new marine compound selected for clinical studies,” Proceedings of the American Association for Cancer Research Annual, No. 41, Mar. 2000, pp. 600-601, XP001097542, 91stAnnual Meeting of the American Association for Cancer Research, San Francisco CA, USA; Apr. 1-5, 2000, Mar. 2000 ISSN: 0197-016X.
Luber-Narod J et al., “Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.” Toxicology In Vitro, vol. 15, No. 4-5, Aug. 2001, pp. 571-577, XP002225749, ISSN: 0887-2333, p. 576, col. 2, paragraph 2.
Brown Alan P et al., “Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.” Cancer Chemotherapy and Pharmacology. Germany Oct. 2002, vol. 50, No. 4, Oct. 2002, pp. 333-340, XP002225750 ISSN: 0344-5704 abstract.
El Sayed, Khalid A. et al., “The Marine Environment: A Resource for Prototype Antimalarial Agents,” Journal of Natural Toxins, vol. 5, No. 2, pp. 261-285, 1996.
Garcia-Rocha, Mar et al., “The antitumoral compound Kahalalide F acts on cell lysosomes,” Cancer Letters, vol. 99, No. 1, pp. 43-50, 1996.
Goetz, Gilles et al., “The Absolute Stereochemistry of Kahalalide F,” Tetrahedron, vol. 55, pp. 7739-7746, 1999.
Goetz, Gilles et al., “Two Acyclic Kahalalides from the Sacoglossan Mollusk Elysia rufescens,” Journal of Natural Products, vol. 60, No. 6, p. 562-567, 1997.
Hamann, Mark T. et al., “Kahalalide F: A Bioactive Depsipeptide from the Sacoglossan MolluskElysia refuscensand the Green Alga Bryopsis sp.,” Journal of the American Chemical Society, vol. 115, No. 13, pp. 5825-5826, 1993.
Hamann, Mark T. et al., “Kahalalides: Bioactive Peptides from a Marine MolluskElysia refuscensand Its Algal Diet Bryopsis sp.,” The Journal of Organic Chemistry, vol. 61, No. 19, pp. 6594-6600, 1996.
Hamann, Mark T. et al., “Kahalalides: Bioactive Peptides from a Marine MolluskElysia refuscensand Its Algal Diet Bryopsis sp.,” The Journal of Organic Chemistry, vol. 63, No. 14, pp. 4856, 1998.
Horgen, F. David et al., “A New Depsipeptide from the Sacoglossan Mollusk Elysia ornate and the Green Alga Bryopsis Species,” Journal of Natural Products, vol. 63, No. 1, pp. 152-154, 2000.
Kan, Yukiko et al., “Kahalalide K: A New Cyclic Depsipeptide from the Hawaiian Green Algo Bryopsis Species,” Journal of Natural Products, vol. 62, No. 8, pp. 1169-1172, 1999.
Lopez-Macia, Angel et al., “Kahalalide B. Synthesis of a natural cyclodepsipeptide,” Tetrahedron Letters, vol. 41, pp. 9765-9769, 2000.
Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw Hill, New York (1996), Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Hamann, Mark Todd, Ph.D., University of Hawaii (1992), “Biologically Active Constituents of Some Marine Invertebrates,” UMI Dissertation Services, published Oct. 1993.
Merck Manual, 11thed., pp. 456-459, 761-763, and 1368-1371; published 1969.
Lee Y S et al., “A convergent liquid-phase synthesis of salmon calcitonin” Journal of Peptide Research, Munksgaard International Publishers, Copenhagen DK, vol. 54, No. 5, Oct. 1999, pp. 328-335, XP000849313 ISSN: 1397-002X, figure 1.
Bonnard Isabelle et al., “Stereochemistry of kahalalide F,” Journal of Natural Products. Nov. 2003, vol. 66, No. 11, Nov. 2003, pp. 1466-1470, XP002337530 ISSN: 0163-3864 abstract.
Lopez-Macia et al., “Synthesis and Structure Determination of Kahalalide F.” J. Am. Chem. Soc., vol. 123, No. 46, pp. 11398-11401, published on web Oct. 27, 2001.
Gura, “Cancer Models-Systems for identifying new drugs are often faulty,” Science, vol. 278, pp. 1041-2, Nov. 7, 1997.
Hartley Michael G.
King & Spalding LLP
Pharma Mar, S.A.U.
Samala Jagadishwar
Sonnenfeld Kenneth H.
LandOfFree
Use of kahalalide compounds for the manufacture of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of kahalalide compounds for the manufacture of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of kahalalide compounds for the manufacture of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3958793